JCI Insight (Nov 2023)

Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens

  • Min Yao,
  • Jonathan Preall,
  • Johannes T.-H. Yeh,
  • Darryl Pappin,
  • Paolo Cifani,
  • Yixin Zhao,
  • Sophia Shen,
  • Philip Moresco,
  • Brian He,
  • Hardik Patel,
  • Amber N. Habowski,
  • Daniel A. King,
  • Kara Raphael,
  • Arvind Rishi,
  • Divyesh Sejpal,
  • Matthew J. Weiss,
  • David Tuveson,
  • Douglas T. Fearon

Journal volume & issue
Vol. 8, no. 21

Abstract

Read online

Intratumoral B cell responses are associated with more favorable clinical outcomes in human pancreatic ductal adenocarcinoma (PDAC). However, the antigens driving these B cell responses are largely unknown. We sought to discover these antigens by using single-cell RNA sequencing (scRNA-Seq) and immunoglobulin (Ig) sequencing of tumor-infiltrating immune cells from 7 primary PDAC samples. We identified activated T and B cell responses and evidence of germinal center reactions. Ig sequencing identified plasma cell (PC) clones expressing isotype-switched and hypermutated Igs, suggesting the occurrence of T cell–dependent B cell responses. We assessed the reactivity of 41 recombinant antibodies that represented the products of 235 PCs and 12 B cells toward multiple cell lines and PDAC tissues and observed frequent staining of intracellular self-antigens. Three of these antigens were identified: the filamentous actin (F-actin), the nucleic protein RuvB like AAA ATPase 2 (RUVBL2), and the mitochondrial protein heat shock protein family D (Hsp60) member 1 (HSPD1). Antibody titers against F-actin and HSPD1 were substantially elevated in the plasma of patients with PDAC compared with healthy donors. Thus, PCs in PDAC produce autoantibodies reacting with intracellular self-antigens, which may result from promotion of preexisting, autoreactive B cell responses. These observations indicate the chronic inflammatory microenvironment of PDAC can support the adaptive immune response.

Keywords